Cipla Tadalafil Tadacip 20mg

Cialis helps increase blood flow to the genitals upon sexual stimulation, enables men with erectile dysfunction (ED) to engage in sustained sexual activity when desired, and helps improve issues such as premature ejaculation in men with varying degrees of ED. New clinical trials have confirmed that it successfully restores sexual function in 65% of patients, regardless of whether the ED is mild, moderate, or severe.

The active ingredient in Cialis, tadalafil, is a selective, reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Cialis is not affected by high-fat meals or moderate alcohol consumption; it is equally effective in patients with ED associated with diabetes, post-prostatectomy ED, and ED following prostate radiotherapy. It is safe and reliable, with few adverse reactions.

[Drug Name]

Generic Name: Tadalafil Tablets

Specification: 20mg × 4 tablets/box

[Ingredients] Tadalafil.

[Appearance] Yellow, almond-shaped.

[Indications] Treatment of erectile dysfunction in men. Sexual stimulation is required for the drug to be effective. Tadalafil is not intended for use by women.

[Dosage and Administration] For oral use in adult men. The recommended initial dose is 20mg, taken prior to sexual activity; administration is not affected by food intake. If the initial 20mg dose is ineffective—or if the patient has previously required a dose higher than 20mg (e.g., 50mg) to achieve results—then a dose exceeding 20mg (such as three 20mg tablets) may be necessary. It can be taken at least 30 minutes before sexual activity. The maximum frequency of administration is once daily. Continuous daily use is not recommended, as the safety of long-term use has not been established; furthermore, the effects of tadalafil often persist for more than 24 hours (see the final paragraph of "Precautions" and the "Pharmacology and Toxicology" section). Use in elderly men: No dosage adjustment is required. Use in men with renal impairment: No dosage adjustment is required for patients with mild to moderate renal impairment. For patients with severe renal impairment, the maximum recommended dose is 20mg. (See "Pharmacokinetics") The recommended dose for men with hepatic impairment is 20 mg, taken prior to sexual activity; administration is not affected by food intake. Clinical safety data regarding the use of tadalafil in patients with severe hepatic impairment (Child-Pugh class C) are limited; if prescribed to such patients, a careful benefit/risk assessment must be conducted by the prescribing physician. There are no data on doses higher than 20 mg in patients with hepatic impairment. ("Precautions" and "Pharmacokinetics") No dose adjustment is required for men with diabetes.

[Adverse Reactions] The most commonly reported adverse reactions are headache and dyspepsia; see the tables below. Table 1: Most common adverse reactions (>1/10) System or Organ | Adverse Reaction | Tadalafil 10–20 mg (%) N=724 | Placebo (%) N=379 | Nervous system | Headache | 14.5 | 5.5 | Gastrointestinal | Dyspepsia | 12.3 | 1.8 | Table 2: Common adverse reactions (>1/100, <1/10) System or Organ | Adverse Reaction | Tadalafil 10–20 mg (%) N=724 | Placebo (%) N=379 | Nervous system | Dizziness | 2.3 | 1.8 | Circulatory system | Flushing | 4.1 | 1.6 | Respiratory, thoracic, and mediastinal | Nasal congestion | 4.3 | 3.2 | Musculoskeletal and connective tissue | Back pain / Myalgia | 6.5 / 4.2 | 5.7 / 1.8 | Eyelid swelling, as well as reports described as eye pain and conjunctival hyperemia, are very rare adverse reactions. Reported adverse reactions associated with tadalafil were transient and mild to moderate in severity. These adverse reaction data apply only to patients under the age of 75.

[Contraindications] Clinical studies indicate that tadalafil potentiates the hypotensive effects of nitrates. This is considered to be the result of the combined effect of nitrates and tadalafil on the nitric oxide/cGMP pathway. Therefore, the use of this product is contraindicated in patients who are taking any form of nitrates. (See "Drug Interactions" for details.) Sexual activity carries a potential cardiac risk for patients with heart disease. Consequently, treatments for erectile dysfunction, including tadalafil, should not be used in patients with heart disease for whom sexual activity is inadvisable. Physicians should consider the potential cardiac risk of sexual activity in patients with pre-existing cardiovascular disease. Clinical trials have not included patients with the following cardiovascular conditions; therefore, tadalafil is strictly contraindicated in these populations: patients who have experienced a myocardial infarction within the last 90 days; patients with unstable angina or angina occurring during sexual intercourse; patients with heart failure classified as NYHA Class 2 or greater within the past 6 months; patients with uncontrolled arrhythmias, hypotension (<90/50 mmHg), or uncontrolled hypertension; and patients who have experienced a stroke within the last 6 months. Patients with a known hypersensitivity to tadalafil or any component of the formulation must not take this product.

[Precautions] Before considering pharmacological treatment, a medical history should be obtained and a physical examination performed to diagnose erectile dysfunction and identify potential underlying causes. Since there is a degree of association between cardiovascular risk and sexual activity, physicians should consider the patient's cardiovascular status before initiating treatment for erectile dysfunction, including the use of tadalafil. Due to its vasodilatory properties, tadalafil causes mild and transient decreases in blood pressure (see "Pharmacology and Toxicology"); this effect may potentiate the hypotensive effects of nitrates (see "Contraindications"). Serious cardiovascular events—including myocardial infarction, unstable angina, ventricular arrhythmias, shock, and transient ischemic attacks—have been observed in clinical trials involving tadalafil. Additionally, hypertension and hypotension (including orthostatic hypotension) have occasionally been reported in clinical trials. Most patients who experienced these events had pre-existing cardiovascular risk factors. However, it is not currently certain whether these events are causally related to these risk factors. Clinical safety data regarding the use of this product in patients with severe hepatic impairment (Child-Pugh class C) are limited; if prescribed to such patients, a careful benefit-risk assessment must be conducted by the prescribing physician. No cases of priapism were reported in clinical trials of tadalafil; however, priapism has been reported with sildenafil, another PDE5 inhibitor. Patients should be advised to seek immediate medical attention if an erection persists for 4 hours or longer. Failure to treat priapism promptly can result in damage to penile tissue and permanent loss of erectile function. Tadalafil should be used with caution in patients predisposed to priapism (e.g., those with sickle cell anemia, multiple myeloma, or leukemia) or in patients with anatomical deformation of the penis (e.g., angulation, cavernosal fibrosis, or Peyronie's disease). Evaluation of erectile dysfunction should include a determination of potential underlying causes and the identification of appropriate treatment following an adequate assessment. The efficacy of this product in patients who have undergone pelvic surgery or radical prostatectomy, or in those with spinal cord injury, is currently unknown. Tadalafil should not be used in patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption. Concomitant use of this product with alpha(1)-blockers (such as doxazosin) may lead to symptomatic hypotension in some patients (see "Drug Interactions"); therefore, the combination of tadalafil and alpha-blockers is not recommended. Particular caution should be exercised when prescribing tadalafil to patients taking potent CYP3A4 inhibitors (e.g., ritonavir, saquinavir, ketoconazole, itraconazole, erythromycin). It has been found that co-administration of tadalafil with drugs of this class increases tadalafil exposure (AUC) (see "Drug Interactions"). The safety and efficacy of combining this product with other treatments for erectile dysfunction have not been studied; therefore, such combinations are not recommended. In a study involving dogs administered tadalafil at doses of 25 mg/kg/day or higher for 6–12 months (resulting in systemic exposure at least 3 times higher [range: 3.7–18.6] than that observed in humans at a single 20 mg dose), degeneration of the seminiferous tubular epithelium was observed in some animals, leading to a decrease in sperm count. Results from two 6-month studies in healthy human volunteers indicated that the clinical phenomena observed in the dog study do not occur in humans (see "Pharmacology and Toxicology"). The effects of long-term, continuous daily use of tadalafil have not been established; therefore, continuous daily use is contraindicated. Tadalafil has no or negligible influence on the ability to drive or operate machinery. Specific studies on this potential effect have not been conducted. Although the incidence of dizziness reported in clinical trials was similar between the placebo and tadalafil groups, patients should be aware of their response to tadalafil before driving or operating machinery.

[Specification] 20 mg × 4 tablets

[Overdose] In healthy subjects, single doses up to 500 mg and multiple daily doses totaling up to 100 mg in patients resulted in adverse events similar to those observed at lower doses. In the event of an overdose, standard supportive care should be administered. Hemodialysis contributes negligibly to the elimination of tadalafil.

[Storage] Store at room temperature.

[Shelf Life] Two years

Important Information for Purchasing Sexual Health Products:

Note: Oral medications for erectile dysfunction in men require sexual stimulation to be effective; they do not automatically induce an erection.

When using drugs containing sildenafil, vardenafil, tadalafil, avanafil, or dapoxetine, many users are concerned about whether the expected results will be achieved. Based on a combination of clinical data and real-world user feedback, the proportion of individuals for whom different medications prove ineffective varies slightly:

Sildenafil: Approximately 15%–20% of users do not achieve the expected results after administration.

Vardenafil: The proportion of non-responders is similar to that of Sildenafil, standing at approximately 15%–22%.

Tadalafil: Due to its longer half-life, this medication is suitable for a slightly broader range of patients; consequently, its failure rate is slightly lower, at approximately 12%–18%.

Avanafil: Characterized by a rapid onset of action and rapid metabolism, the proportion of non-responders is approximately 14%–19%.

Priligy: Specifically designed to treat premature ejaculation, this medication is more heavily influenced by individual neurological sensitivity and psychological state; as a result, its failure rate is relatively higher, at approximately 20%–25%.

It is crucial to clarify that for some individuals, a lack of efficacy is by no means an indication of a product quality issue; rather, it is the result of the interplay between the drug's mechanism of action and the individual's unique physiological and pathological conditions. Even the original brand-name products—such as Pfizer's Viagra (Sildenafil)—are known to be ineffective for a significant proportion of users (approximately 20% of men experience no effect), and this is not attributed to product quality defects. With many male enhancement products, it is common to encounter scenarios where—even with the exact same box of medication—it proves effective for one person but ineffective for another; conversely, switching to a different product may yield results for the second person while proving ineffective for the first. This store guarantees that all sexual health products sold here are 100% authentic; however, we cannot guarantee that 100% of users will achieve their desired results. We strongly urge you to carefully consider these factors before placing an order. Specific reasons vary by medication:

Sildenafil / Vardenafil / Avanafil: All three work by promoting vasodilation. Their effectiveness is influenced by individual metabolic capacity (liver and kidney function affecting the rate of drug breakdown), underlying medical conditions (e.g., diabetes or hypertension damaging blood vessels and reducing drug efficiency), and the context of use (alcohol consumption can inhibit effects, while high-fat meals may delay the absorption of Sildenafil and Vardenafil). In cases of severe arterial disease, the medication struggles to facilitate blood flow, naturally limiting its efficacy.

Tadalafil: Although its mechanism of action is similar to the three drugs mentioned above, it remains in the body for a longer duration. However, its effectiveness is still influenced by factors such as individual drug sensitivity and the presence of severe prostate disease or spinal cord injuries; some individuals may experience suboptimal results due to weaker receptor binding affinity.

Priligy (Dapoxetine): Works by inhibiting neurotransmitter reuptake to improve ejaculation control. Its effectiveness is closely linked to individual nerve conduction efficiency, psychological state (anxiety or tension can counteract the drug's effects), and whether the dosage is appropriate for the patient's body weight and the severity of the condition. If there is abnormal nerve sensitivity or long-standing psychogenic premature ejaculation, the drug's regulatory effect may be limited.

If the results from using any of the aforementioned medications or dual-effect tablets fall short of expectations, do not arbitrarily increase the dosage, switch medications, or continue taking them blindly over the long term. Instead, consult a urologist or andrologist promptly. A doctor will assess your physical condition through a detailed consultation and, based on test results, adjust your treatment plan (e.g., optimizing dosage or changing the type of medication) or incorporate psychological interventions and behavioral training to create a solution better suited to your needs.

Specifications

Product Name: Tadalafil Tablets (Cialis) 20mg x 4 Tablets (Cipla Tadalafil Tadacip 20mg)

Common Name: Cialis

Active Ingredient: Tadalafil

Dosage Form: Tablet

Specification: 1 box (4 tablets)

Manufacturer: Cipla Pharmaceuticals

Indication: Treatment of male erectile dysfunction. Sexual stimulation is required for the medication to be effective. Dosage and Administration: For adult men, the recommended initial dose of tadalafil is 20 mg, taken prior to sexual activity; administration is unaffected by food intake. If the initial 20 mg dose is ineffective—or if the patient has previously required a single dose exceeding 20 mg (e.g., 50 mg) to achieve the desired effect—then a dose greater than 20 mg (such as three 20 mg tablets) may be required. It may be taken at least 30 minutes before sexual activity. The maximum frequency of administration is once daily. Continuous daily use is not recommended, as the safety of long-term use has not been established; furthermore, the effects of tadalafil often persist for more than one day (see the final paragraph of "Precautions" and the "Pharmacology and Toxicology" section). Elderly men: No dosage adjustment is required. Men with renal impairment: No dosage adjustment is required for patients with mild to moderate renal impairment. For patients with severe renal impairment, the maximum recommended dose is 20 mg (see "Pharmacokinetics"). Men with hepatic impairment: The recommended dose is 20 mg, taken prior to sexual activity; administration is unaffected by food intake. Clinical safety data regarding the use of tadalafil in patients with severe hepatic impairment (Child-Pugh Class C) are limited; if prescribed to such patients, a careful benefit-risk assessment must be conducted by the prescribing physician for each individual. There are no data on doses exceeding 20 mg in patients with hepatic impairment (see "Precautions" and "Pharmacokinetics"). Men with diabetes: No dosage adjustment is required.